Page 29 - Read Online

Page 24 of 27 J Cancer Metastasis Treat 2019;5:5 I http://dx.doi.org/10.20517/2394-4722.2018.108
2 Cancer Genomics Laboratory, Fondazione Edo ed Elvo Tempia, Biella 13900, Italy.
3 Oncology Unit, Department of Translational Medicine, Università del Piemonte Orientale “A. Avogadro”,
Novara 28100, Italy.

Introduction: Biological processes are regulated through epigenetics, including chromatin remodelling
(methylation, acetylation, etc.) and non coding RNAs. The correct balance of these mechanisms is crucial for
the maintenance of cellular homeostasis and its dysregulation is correlated to many disorders such as cancer.
Nutrient availability has a great impact on the metabolic pathways involved in cancer cell proliferation.
Incubation in Earle’s Balanced Salt Solution (EBSS), a culture medium containing 1% glucose in absence of
serum and amino acids, mimics the condition of starvation. Resveratrol (RV), a dietary polyphenol acting as
a protein (caloric) restriction mimetic makes the cells unable to uptake nutrients for their metabolism.

Results: Here, we report on the changes of the miRNAs in ovarian cancer cells subjected to amino acid
starvation or to RV. In this fasting condition, cancer cells promote autophagy as a pro-survival mechanism
and eventually exit the cell cycle to undergo a dormant state. RV has a major impact on miRNome involved
in autophagy and apoptosis compared to the one observed in EBSS-treated cells.

Conclusion: Our data support the view that RV treatment can be more effective than nutrient starvation,
thus it can substitute it in order to induce a dormant-like state in cancer cells.

33. KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in MCL receiving

high-dose therapy: a fil study

1
1
5
4,5
Chiara Favini , Riccardo Moia , Fary Diop , Simone Ferrero , Davide Rossi , Andrea Rinaldi ,
1
2,3
5
6
Alessio Bruscaggin , Valeria Spina , Andrea Evangelista , Ivo Kwee 5,7,8 , Alice Di Rocco , Vittorio
9
5
11
10
12
2
Stefoni , Paola Ghione , Daniela Barbero , Domenico Novero , Marco Paulli , Alberto Zamò 13,14 ,
2
Maria Gomes da Silva , Armando Santoro , Annalia Molinari , Andres Ferreri , Andrea
18
17
16
15
19
20
Piccin , Sergio Cortelazzo , Francesco Bertoni , Marco Ladetto , Gianluca Gaidano 1
5
21
1 Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara
28100, Italy.
2 Department of Molecular Biotechnologies and Health Sciences - Hematology Division, Università di Torino,
Torino 10126, Italy.
3 Hematology Division, AOU Città della Salute e della Scienza di Torino, Torino 10126, Italy.
4 Hematology, Oncology Institute of Southern Switzerland, Bellinzona 6500, Switzerland.
5 Universita’ della Svizzera italiana, Institute of Oncology Research, Bellinzona 6500, Switzerland.
6 Clinical Epidemiology, Città della Salute e della Scienza and CPO Piemonte, Torino 10126, Italy.
7 Swiss Institute of Bioinformatics (SIB), Lausanne 1015, Switzerland.
8 Dalle Molle Institute for Artificial Intelligence (IDSIA), Manno CH-6928, Switzerland.
9 Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, “Sapienza” University of
Rome, Roma 00185, Italy.
10 Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna 40126, Italy.
11 First unit of Pathology, AOU Città della Salute e della Scienza di Torino, Torino 10126, Italy.
12 Unit of Anatomic Pathology, Department of Molecular Medicine, Fondazione IRCCS Policlinico San Matteo
and Università degli Studi di Pavia, Pavia 27100, Italy.
13 Department of Oncology, Università di Torino, Torino 10126, Italy.
14 Department of Diagnostics and Public Health, University of Verona, Verona 37129, Italy.
15 Department of Hematology, Instituto Português de Oncologia de Lisboa, Lisboa 1099-023, Portugal.